Aspira Women’s Health (NASDAQ: AWHL) files Form 4 for 198,097 director stock options

Rhea-AI Filing Summary

Aspira Women's Health Inc. reported an insider equity award for a director. A Form 4 filing shows that on 12/02/2025 a director received a stock option (right to buy) covering 198,097 shares of Aspira Women's Health common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. Following this grant, the director beneficially owns 198,097 derivative securities, held in direct ownership form.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beausang Ellen

(Last) (First) (Middle)

C/O ASPIRA WOMEN'S HEALTH INC

12117 BEE CAVES RD, BLDG 3-100

(Street)

AUSTIN, TX 78738

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.35	12/02/2025		A		198,097		12/02/2025	12/02/2035	Common Stock	198,097	$0	198,097	D

Explanation of Responses:

	/s/ Ellen Beausang	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Aspira Women's Health Inc. (AWHL) report?

Aspira Women's Health Inc. reported a stock option grant to a director. The option covers 198,097 shares of common stock at an exercise price of $0.35 per share, with an exercisable date of 12/02/2025 and an expiration date of 12/02/2035.

Who is the reporting person in the Aspira Women's Health (AWHL) Form 4?

The Form 4 is signed /s/ Ellen Beausang, indicating she is the reporting person. The filing identifies her relationship to Aspira Women's Health Inc. as a director.

How many derivative securities does the Aspira Women's Health (AWHL) director own after this transaction?

After the reported transaction, the director beneficially owns 198,097 derivative securities in the form of stock options linked to Aspira Women's Health common stock.

What are the key terms of the Aspira Women's Health (AWHL) stock option grant?

The stock option is a right to buy Aspira Women's Health common stock, covering 198,097 shares at an exercise price of $0.35 per share. It is first exercisable on 12/02/2025 and expires on 12/02/2035.

Is the Aspira Women's Health (AWHL) stock option held directly or indirectly?

The Form 4 indicates that the 198,097 stock options are held in direct (D) ownership by the reporting person.

What type of SEC form did Aspira Women's Health (AWHL) use for this director award?

The insider transaction was reported on an SEC Form 4, which discloses changes in the beneficial ownership of a company's securities by its officers, directors, and certain shareholders.